Drugs and FDA
FDA approves Livsayis as first siRNA therapy for myasthenia gravis
Livsayis is approved for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies and is given by injection four times a year.

The FDA approved Regeneron’s Livsayis, also called cemdisiran, for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the company announced. It is the first approved small interfering RNA therapy for the condition and is given by subcutaneous injection four times a year.
Approval was based on the 24-week phase III NIMBLE trial. MedPage Today reported that MG-ADL scores improved from baseline by 4.5 points with cemdisiran and 2.2 points with placebo, an adjusted improvement of 2.3 points (P=0.0005). At 24 weeks, QMG scores improved by 4.2 points with the drug and 1.5 points with placebo, an adjusted improvement of 2.8 points (P=0.0015). MG-ADL improvements were seen as early as 2 weeks.
The drug carries a boxed warning for serious and life-threatening meningococcal infections and is available only through a risk evaluation and mitigation strategy program, Regeneron said. MedPage reported serious adverse events in 3% of the cemdisiran group and 14% of placebo participants.


